- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07951736
Posterior Default Network Modulation in Alcohol Use Disorder
This proposal will test whether repetitive transcranial magnetic stimulation (rTMS) modulation of the brain's posterior default mode network (pDMN) will alter alcohol craving, alcohol seeking and impulsivity in men and women who have an alcohol use disorder but are not seeking treatment.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Alcohol use disorder is a common medical condition affecting the lives of individuals worldwide. Many receive no treatment and relapse is high in those who do; there is a clear need for new and more effective treatments. This project will test whether the pDMN, a large-scale brain circuit most active at rest, is a potential target for therapeutic interventions.
rTMS non-invasively modulates regional cortical activity. Theta burst stimulation (TBS) is a variant of rTMS that utilizes two common patterns, continuous (cTBS) and intermittent (iTBS). This project will test the ability of cTBS and iTBS to change pDMN function, and affect alcohol seeking, alcohol craving, and impulsivity. A sham TBS treatment will be used for comparison.
Sixty participants with mild to moderate alcohol use disorder, who are not seeking treatment, will undergo baseline characterization for alcohol cue responsivity and delay discounting. They will then undergo three experimental days, in random order: (i) sham TBS, (ii) continuous (cTBS), or (iii) intermittent (iTBS). TBS will be delivered twice each experimental day. In the morning, TBS will be followed by a functional magnetic resonance imaging (fMRI) session that includes testing brain responses to alcohol and other taste cues, and delay discounting. Blood oxygenation level dependent (BOLD) contrasts will assess changes within relevant brain structures and across functional brain circuits. In the afternoon, TBS will be followed by an alcohol self-administration session during which small intravenous infusions of alcohol can be earned on a progressive ratio schedule. Number of infusions earned will be used to assess changes in alcohol motivation after TBS treatment.
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Ann E Kosobud, PhD
- Numéro de téléphone: 3172740087
- E-mail: akosobud@iu.edu
Sauvegarde des contacts de l'étude
- Nom: James M Hays
- Numéro de téléphone: 3179486550
- E-mail: haysjm@iu.edu
Lieux d'étude
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46201
- IU Health University Hospital
-
Chercheur principal:
- Martin H Plawecki, MD, PhD
-
Contact:
- Study Recruiter
- Numéro de téléphone: 3179486551
- E-mail: erptest@iu.edu
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Men and women aged 21 - 55
- Alcohol Use Disorder diagnostic criteria based on Interview, Screening, and Measures of at least moderate severity
- ≥7 or 14 drinks/week average over the last month or ≥ 3 or 4 drinks/occasion for women and men respectively
- Positive alcohol cue reactivity screening
- Systematic Delay Discounting behavior
- Right-handed
Exclusion Criteria:
- Physical Exam, Vital Signs, Electrocardiogram, Laboratory Values, or screening assessment precluding safe participation or experimental procedures
- Clinical Institute Withdrawal Assessment for Alcohol (CIWA) 177 ≥8 or reported significant risk symptoms
- MRI contraindications
- Pregnant or breast-feeding women; Women who do not attest to using accepted forms of birth control
- Current or desire for AUD or substance use treatment
- Medical conditions (e.g., seizure disorder) that may influence participant safety or study outcome)
- Positive urine drug screen for amphetamines/ methamphetamines, barbiturates, benzodiazepines, cocaine, opiates, or phencyclidine and evidence of intoxication
- Medications or dosage changes (past 30 days) that could influence participant safety or data (e.g., antidepressants, antipsychotics, benzodiazepines, etc.) or interact with alcohol
- Current/history of neurological disease of cerebral origin, head injury with > 20 min loss of consciousness, medical treatment impacting MRI data, or serious psychiatric illness (bipolar disorder, psychosis).
- Positive BrAC reading precluding visit completion
- Actively suicidal or are at serious suicidal risk
- Left-handed or ambidextrous
- First degree family member with seizure disorder
- Inability to understand English study instructions
- Intoxication from any substance terminates an experimental day and will be considered for overall exclusion or study participation.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Sequence 1
On each of the three experimental study days, participants will undergo one of the following TBS treatment conditions: sham, continuous, or intermittent. Participants will receive all three treatment conditions in a randomly assigned order. To ensure participant blinding, the treatment order of this assigned sequence cannot be disclosed until the trial is concluded. An IV alcohol self-administration session is conducted on each study day. Use of IV alcohol solutions is allowed under an FDA IND. It is a research tool and is not being tested for clinical use. |
cTBS consists of a continuous train of 3-pulse bursts of neurostimulation. iTBS consists of 2 second trains of 3-pulse bursts of neurostimulation, alternating with 8 seconds of rest. Sham TBS duplicates the peripheral sensations of TBS without neurostimulation Sterile alcohol is mixed with USP saline to a concentration of 6% |
|
Expérimental: Sequence 2
On each of the three experimental study days, participants will undergo one of the following TBS treatment conditions: sham, continuous, or intermittent. Participants will receive all three treatment conditions in a randomly assigned order. To ensure participant blinding, the treatment order of this assigned sequence cannot be disclosed until the trial is concluded. An IV alcohol self-administration session is conducted on each study day. Use of IV alcohol solutions is allowed under an FDA IND. It is a research tool and is not being tested for clinical use. |
cTBS consists of a continuous train of 3-pulse bursts of neurostimulation. iTBS consists of 2 second trains of 3-pulse bursts of neurostimulation, alternating with 8 seconds of rest. Sham TBS duplicates the peripheral sensations of TBS without neurostimulation Sterile alcohol is mixed with USP saline to a concentration of 6% |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in pDMN BOLD responses to alcohol taste after iTBS, cTBS or sham treatment.
Délai: 3 single day laboratory sessions scheduled 7-14 days apart
|
During the fMRI scan, two taste tests will be run, one alternating brief exposures to a preferred alcohol beverage and water, and a second alternating a sports drink with water. The primary comparison will be BOLD contrast [Flavor > Water] (where 'Flavor' is alcohol or sports drink) in the posterior default mode network (pDMN). Changes in response to alcohol-specific taste after iTBS, cTBS or sham treatments will be compared using linear or linear mixed models, controlling for age, biological sex, smoking, and subjective ratings (flavor liking and intensity, craving changes from baseline) and adjusting for multiple comparisons across regions. |
3 single day laboratory sessions scheduled 7-14 days apart
|
|
Change in cue-induced craving after TBS.
Délai: 3 single day laboratory sessions scheduled 7-14 days apart
|
In the Alcohol Cue Reactivity screen (ACR), a participant rates their current craving for alcohol before and after a 3 minute exposure to their preferred alcohol beverage in its typical glass (looking, smelling and handling the glass but not drinking). The ACR will be conducted before and after the morning TBS treatment. Change in alcohol craving after cTBS, iTBS or sham treatments will be compared using a linear or linear mixed model. |
3 single day laboratory sessions scheduled 7-14 days apart
|
|
Change in the number of completed trials and alcohol infusions earned on a progressive ratio task after TBS.
Délai: 3 single day laboratory sessions scheduled 7-14 days apart
|
During the alcohol infusion session, participants will be able to earn transient increases in infusion flow rate by completing a button pressing task. Number of trials required will increase after each earned infusion. The breakpoint is defined as the number of trials completed for the last infusion earned. Breakpoints after iTBS, cTBS and sham treatments will be compared using a linear or linear mixed model. |
3 single day laboratory sessions scheduled 7-14 days apart
|
|
Change in impulsivity assessed using a delay discounting task after TBS.
Délai: 3 single day laboratory sessions scheduled 7-14 days apart
|
Delay discounting estimates impulsivity by measuring preference for immediate versus delayed rewards. To optimize the task for scanning, monetary values and starting delays will be based on an individual's performance on the task during the interview. Changes in impulsivity after cTBS, iTBS and sham treatments will be assessed using a linear or linear mixed model. |
3 single day laboratory sessions scheduled 7-14 days apart
|
|
Change in pDMN BOLD responses during a delay discounting task after TBS.
Délai: 3 single day laboratory sessions scheduled 7-14 days apart
|
BOLD responses within the pDMN measured during the delay discounting task will be compared after cTBS, iTBS and sham treatments. Intervention (sham vs cTBS, and sham vs iTBS) and Group (sham-cTBS and sham-iTBS) contrasts will be assessed using linear or linear mixed models, controlling for age, biological sex, smoking, and subjective ratings (flavor liking and intensity, craving changes from baseline) and adjusting for multiple comparisons across regions. |
3 single day laboratory sessions scheduled 7-14 days apart
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in pDMN functional connectivity during alcohol tasting after TBS treatment.
Délai: 3 single day laboratory sessions scheduled 7-14 days apart
|
In separate scans, brief exposures to a preferred alcohol beverage or a sports drink will be alternated with water. Functional network connectivity will be assessed by calculating changes in the correlation between pairs of nodes within the pDMN. |
3 single day laboratory sessions scheduled 7-14 days apart
|
|
Change in functional connectivity between the pDMN and salience network after TBS.
Délai: 3 single day laboratory sessions scheduled 7-14 days apart
|
The effect of TBS treatments on functional network connectivity will be assessed by calculating changes in the correlation between pairs of nodes within the pDMN and the salience network. The difference in connectivity estimates after cTBS, iTBS and sham TBS will be assessed using linear mixed models. |
3 single day laboratory sessions scheduled 7-14 days apart
|
|
Change in within-DMN functional connectivity during a delay discounting task after TBS.
Délai: 3 single day laboratory sessions scheduled 7-14 days apart
|
During the delay discounting task, functional connectivity will be estimated from regional BOLD time series using Pearson correlations. Pairwise connectivity estimates will be computed for predefined region of interest pairs within the pDMN. The difference in connectivity estimates after cTBS, iTBS and sham TBS will be assessed using linear mixed models. |
3 single day laboratory sessions scheduled 7-14 days apart
|
|
Change in functional connectivity between the pDMN and cognitive control areas after TBS.
Délai: 3 single day laboratory sessions scheduled 7-14 days apart
|
Exploratory assessments will be conducted to detect other potentially important effects of TBS on connectivity between the pDMN and cognitive control areas. Contrasts between cTBS and iTBS will be compared during delay discounting and alcohol tasting. |
3 single day laboratory sessions scheduled 7-14 days apart
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Martin H Plawecki, MD, PhD, Department of Psychiatry, Indiana University School of Medicine
- Chercheur principal: David Kareken, PhD, Department of Neurology, Indiana University School of Medicine
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 24457
- R01AA031671 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
We will contribute date to the National Data Archive as required by NIH. The final raw dataset will be available to other researchers when we have collected all subjects and completed our own planned analyses. Prior to completion of our own planned analyses, we would be willing to consider releasing the dataset upon request. We will work with our IRB to establish a strategy for de-identifying the data while retaining the ability to ensure the quality of the stored data.
Délai de partage IPD
After all subjects have been collected and the primary outcomes accepted for publication. The dataset will be available indefinitely,
Critères d'accès au partage IPD
On request to the PIs
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- CIF
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .